Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Hematol Oncol Stem Cell Ther ; 3(2): 94-8, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20543544

RESUMO

An 18-year-old male underwent an allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myeloid leukemia (CML) in the first late chronic phase. On day 132, he was readmitted to the hospital with nausea, vomiting and nodular lesions on endoscopy. A diagnosis of granulocytic sarcoma of the stomach was made. Bone marrow cytogenetic analysis for the Philadelphia chromosome and nested polymerase chain reaction for BCR-ABL1 were both negative. Immunosuppression was abruptly discontinued, and by day 180, all gastric lesions had completely disappeared. However, there were histological signs of graft-versus-host disease. The patient developed progressive anorexia and elevated hepatic enzymes, which prompted the reintroduction of cyclosporine. Considering the risk of another relapse, imatinib mesylate (IM) 600 mg/day was started. The patient Is condition improved, and there was no evidence of disease recurrence at 36 months after relapse. Relapse of CML is the commonest cause of treatment failure after allo-HSCT. On rare occasions, a localized extramedullary presentation is seen. Unless properly treated, other extramedullary relapse sites and/or marrow infiltration usually occur. Withdrawal of immunosuppression, along with IM therapy seems to be an acceptable approach in this setting.


Assuntos
Antineoplásicos/administração & dosagem , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Segunda Neoplasia Primária , Piperazinas/administração & dosagem , Pirimidinas/administração & dosagem , Sarcoma Mieloide , Neoplasias Gástricas , Adolescente , Benzamidas , Transplante de Células-Tronco Hematopoéticas , Humanos , Mesilato de Imatinib , Terapia de Imunossupressão/efeitos adversos , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Masculino , Segunda Neoplasia Primária/tratamento farmacológico , Segunda Neoplasia Primária/patologia , Sarcoma Mieloide/tratamento farmacológico , Sarcoma Mieloide/patologia , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/patologia , Transplante Homólogo
4.
Hepatogastroenterology ; 55(84): 850-4, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18705281

RESUMO

BACKGROUND/AIMS: The objective of the present study was to measure gastric emptying time of solids and semisolids in dyspeptic individuals with cholecystolithiasis before and 6 months after cholecystectomy in order to determine whether cholecystectomy interferes with gastric emptying. METHODOLOGY: A prospective, self-pairing study was conducted on 29 patients selected according to appropriate inclusion and exclusion criteria. Gastric emptying time of solids and semisolids was determined before and six months after laparoscopic cholecystectomy by the 13C-octanoic acid and 13C-acetate breath tests, respectively. The samples were analyzed by infrared spectrometry. The gastric retention time (lag phase) and gastric emptying half-time of solid and semisolid were determined and the results obtained before and after surgery were compared in the same patient. In addition, the effects of surgery on dyspeptic symptoms were assessed. RESULTS: No significant differences (p>0.05) in gastric retention time and gastric emptying half-time of solid and semisolid test meals were observed before and after cholecystectomy. Dyspeptic symptoms (pain, upper abdominal gases, early satiety, nausea and vomiting) improved after surgery. CONCLUSIONS: Laparoscopic cholecystectomy does not interfere with the gastric emptying time of solids or semisolids in dyspeptic individuals with cholecystolithiasis.


Assuntos
Testes Respiratórios , Colecistectomia , Dispepsia/cirurgia , Cálculos Biliares/cirurgia , Esvaziamento Gástrico/fisiologia , Adolescente , Adulto , Idoso , Caprilatos , Isótopos de Carbono , Dispepsia/fisiopatologia , Feminino , Seguimentos , Cálculos Biliares/fisiopatologia , Gastroparesia/fisiopatologia , Gastroparesia/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Valores de Referência , Acetato de Sódio , Espectrofotometria Infravermelho
5.
Helicobacter ; 12(5): 572-4, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17760728

RESUMO

UNLABELLED: Recent in vitro studies suggest that propolis and some of its phenolic components are able to inhibit Helicobacter pylori growth. To date, there are no clinical studies. AIMS: To evaluate the effect of Brazilian green propolis on H. pylori-infected individuals. PATIENTS AND METHODS: Eighteen (11 females, 7 males, mean age 47 years) participants were included. Before treatment, all participants were submitted to gastroscopy, and H. pylori infection was confirmed by histology, urease test, and (13)C-urea breath test (UBT). Participants with UBT showing a delta over baseline (DOB) value higher than 4 per thousand were considered positive for H. pylori infection. Twenty drops from an alcoholic preparation of Brazilian green propolis were administered three times a day for 7 days. Clinical evaluation and UBT were performed at 1-3 days and at 40 days after the end of therapy to evaluate H. pylori suppression or eradication, respectively. RESULTS: All participants took all medication and completed the study. Eighty-three percent of the subjects did not succeed in suppressing or eradicating H. pylori. Two participants reached partial suppression after treatment, but became positive again at UBT performed 40 days after treatment. Another participant presented negative at UBT 40 days after treatment, not confirmed by a second UBT performed 100 days after treatment. CONCLUSIONS: Brazilian green propolis used in popular dose showed minimal effect on H. pylori infection. Larger studies with longer duration, larger dose, and different frequency of administration of propolis extract should be undertaken to define its role on H. pylori therapy.


Assuntos
Anti-Infecciosos/uso terapêutico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori/efeitos dos fármacos , Própole/uso terapêutico , Anti-Infecciosos/administração & dosagem , Brasil , Feminino , Infecções por Helicobacter/diagnóstico , Infecções por Helicobacter/microbiologia , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Própole/administração & dosagem , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...